Proceedings of the National Academy of Sciences, Volume 122, Issue 45, November 2025. SignificanceAn anti-influenza therapeutic was developed, based on the use of a nanobody that recognizes all mouse immunoglobulin kappa light chains (VHHkappa), covalently modified with 4 molecules of the influenza neuraminidase inhibitor zanamivir. This …

Read original article